Key takeaways
Zinbryta (daclizumab) and Lemtrada (alemtuzumab) are both used to treat relapsing forms of multiple sclerosis (MS) in adults, but they have notable differences. Zinbryta is a monoclonal antibody that helped lower inflammationin the brain. However, it was discontinued in the United States due to safety concerns, including liver injury and immune-related problems. In contrast, Lemtrada, an anti-CD52 monoclonal antibody, is still available but only for those who haven't responded well to at least two other MS medications. Lemtrada is administered as an annual IV infusion, after the first treatment course. It has a high risk of serious side effects, such as developing autoimmune problems, infections, and cancer, and is only available through a special REMS program.
